All In Biotech

Drug Trial Radar · NCT05849272

Efficacy and Safety of Toluedesvenlafaxine Hydrochloride Extended-release Tablets in Somatic Symptoms of Depression

Efficacy and Safety of Toluedesvenlafaxine Hydrochloride Extended-release Tablets in Somatic Symptoms of Depression: a Prospective, Single-arm, Multicenter Study

Last checked: Nov 20, 2026Latest source record: May 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

May 12, 2023

Primary completion

May 8, 2024

Study completion May 8, 2024

Sponsor

Lead sponsor
Shanghai Mental Health CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in the treatment of somatic symptoms in depression, to provide evidence-based basis for clinical rational drug use.

Conditions

  • Somatic Symptom

Interventions

  • toludesvenlafaxine hydrochloride sustained-release tabletsDrug

    orally once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient Health Questionnaire-15 (PHQ-15)Time frame: 8 Weeks
  2. The Chinese version of the Somatization Symptom Scale (SSS-CN)Time frame: 8 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Mental Health Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.